Overview
- The National Cancer Center and Keio University analyzed records from June 2019 to June 2024 and released the results on January 8 in an international journal.
- Targetable genetic alterations were identified in 72.7% of tested solid-tumor patients.
- Only 8.0% received matched therapy overall, with uptake increasing from 5.5% in 2019–20 to 10.0% in 2023–24.
- Treatment linkage varied by cancer type, reaching 34.8% in thyroid cancer and 20.3% in non-small cell lung cancer, but about 1% in pancreatic and liver cancers.
- Patients who received matched therapy tended to live longer, with the strongest results from domestically approved drugs and relatively favorable outcomes via clinical trials or the patient-requested therapy pathway.